PMID- 31982279
OWN - NLM
STAT- MEDLINE
DCOM- 20200911
LR  - 20200911
IS  - 1532-2653 (Electronic)
IS  - 0967-5868 (Linking)
VI  - 74
DP  - 2020 Apr
TI  - Impact of adverse events of bevacizumab on survival outcomes of patients with 
      recurrent glioblastoma.
PG  - 36-40
LID - S0967-5868(19)32172-1 [pii]
LID - 10.1016/j.jocn.2020.01.066 [doi]
AB  - BACKGROUND: Bevacizumab is widely used for treatment of recurrent glioblastoma 
      (rGB). It is well known that adverse events (AEs) due to bevacizumab can cause 
      early discontinuation of treatment. However, the association between AEs and 
      survival outcomes is not well defined. METHODS: We retrospectively identified 
      patients with rGB, who were treated with single-agent bevacizumab or 
      bevacizumab-based combination regimens from 07/2005 through 07/2014, and who 
      discontinued bevacizumab due to either AEs or physician's decision. Those who 
      discontinued bevacizumab because of tumor progression were excluded. Demographic, 
      treatment, and survival data were collected from the database. RESULTS: Of 298 
      adults with rGB treated with bevacizumab in our database, 65 patients 
      discontinued bevacizumab due to AEs (n = 39, 60%) or physician's decision 
      (n = 26, 40%). There were no statistically significant differences in regards to 
      age, performance status, extent of resection, number of lesions, the time between 
      diagnosis and first recurrence, time between diagnosis and initiation of 
      bevacizumab, number of recurrences before bevacizumab initiation, and duration of 
      bevacizumab treatment between the two groups. Interestingly, patients who 
      discontinued bevacizumab because of AEs progressed earlier after bevacizumab 
      discontinuation (3.9 months vs 5.7 months; p = 0.02), had significantly shorter 
      progression-free survival (PFS) (10.4 months vs 14.2 months; p = 0.01) and 
      shorter overall survival (OS) from bevacizumab initiation (13.9 months vs 
      32.5 months; p = 0.01) as well as shorter OS from tumor diagnosis (20 months vs 
      49.3 months; p = 0.007) when compared to patients who discontinued bevacizumab 
      due to a physician's decision. CONCLUSIONS: Our results indicate that the 
      development of AEs to bevacizumab or bevacizumab-containing regimens is 
      associated with unfavorable glioma-related survival outcomes in patients with 
      rGB.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Kamiya-Matsuoka, Carlos
AU  - Kamiya-Matsuoka C
AD  - Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, United States. Electronic address: ckamiya@mdanderson.org.
FAU - Hamza, Mohamed A
AU  - Hamza MA
AD  - Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, United States; OhioHealth, Columbus, OH, United States.
FAU - de Groot, John F
AU  - de Groot JF
AD  - Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, United States.
LA  - eng
PT  - Journal Article
DEP - 20200123
PL  - Scotland
TA  - J Clin Neurosci
JT  - Journal of clinical neuroscience : official journal of the Neurosurgical Society 
      of Australasia
JID - 9433352
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents, Immunological/adverse effects
MH  - Bevacizumab/*adverse effects
MH  - Clinical Decision-Making
MH  - Female
MH  - Glioblastoma/drug therapy/*mortality/pathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/drug therapy/mortality/pathology
MH  - Progression-Free Survival
MH  - Retrospective Studies
MH  - Withholding Treatment
OTO - NOTNLM
OT  - Adverse events
OT  - Bevacizumab
OT  - Physician's decision
OT  - Recurrent glioblastoma
OT  - Survival
EDAT- 2020/01/27 06:00
MHDA- 2020/09/12 06:00
CRDT- 2020/01/27 06:00
PHST- 2019/11/03 00:00 [received]
PHST- 2020/01/12 00:00 [accepted]
PHST- 2020/01/27 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
PHST- 2020/01/27 06:00 [entrez]
AID - S0967-5868(19)32172-1 [pii]
AID - 10.1016/j.jocn.2020.01.066 [doi]
PST - ppublish
SO  - J Clin Neurosci. 2020 Apr;74:36-40. doi: 10.1016/j.jocn.2020.01.066. Epub 2020 
      Jan 23.